Current development in novel drug delivery systems of bioactive molecule plumbagin

References

• Salanki A, Kutty SK. Plant derived compounds in clinical trials. Drug Discov Today. 2007;13:161–171.
   PubMed Web of Science ®Google Scholar
• Saraf AS. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010;81:680–689.
   PubMed Web of Science ®Google Scholar
• Sumsakul W, Karbwang J, Na-Bangchang K. Application of SPECT/CT imaging system and radiochemical analysis for investigation of blood kinetics and tissue distribution of radiolabelled plumbagin in healthy and Plasmodium berghei-infected mice. Exp Parasitol. 2016;161:54–61.
   PubMed Web of Science ®Google Scholar
• Kawiak A, Zawacka-Pankau J, Lojkowska E. Plumbagin induces apoptosis in Her2-overexpressing breast cancer cells through the mitochondrial-mediated pathway. J Nat Prod. 2012;75:747–751.
   PubMed Web of Science ®Google Scholar
• Hazra B, Sarkar R, Bhattacharyya S, et al. Synthesis of plumbagin derivatives and their inhibitory activities against Ehrlich ascites carcinoma in vivo and Leishmania donovani Promastigotes in vitro. Phytother Res. 2002;16:133–137.
   PubMed Web of Science ®Google Scholar
• Jackson JK, Higo T, Hunter WL, et al. Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res. 2008;57:126–134.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Deng W, Kang R, et al. Plumbagin protects mice from lethal sepsis by modulating immunometabolism upstream of PKM2. Mol Med. 2016;22:162–172.
   PubMed Web of Science ®Google Scholar
• Sankar R, Devamanoharan P, Raghupathi G, et al. Lipid peroxidation in plumbagin administered rats. J Biosci. 1987;12:267–271.
   Web of Science ®Google Scholar
• Suraveratum N, Krungkrai SR, Leangaramgul P, et al. Purification and characterization of Plasmodium falciparum succinate dehydrogenase. Mol Biochem Parasitol. 2000;105:215–222.
   PubMed Web of Science ®Google Scholar
• Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008;68:9024–9032.
   PubMed Web of Science ®Google Scholar
• Chen CA, Chang HH, Kao CY, et al. Plumbagin, isolated from Plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells. Pancreatology. 2009;9:797–809.
   PubMed Web of Science ®Google Scholar
• Sandur SK, Pandey MK, Sung B, et al. 5-Hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res. 2010;8:107–118.
   PubMed Web of Science ®Google Scholar
• Xu TP, Shen H, Liu LX, et al. Plumbagin from Plumbago zeylanica L. induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asian Pac J Cancer Prev. 2013;14:2325–2331.
   PubMedGoogle Scholar
• Hsu YL, Cho CY, Kuo PL, et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 2006;318:484–494.
   PubMed Web of Science ®Google Scholar
• Shieh JM, Chiang TA, Chang WT, et al. Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-kappaB and AP-1 via ERK harmacody pathway in A549 human lung cancer cells. Mol Cell Biochem. 2010;335:181–193.
   PubMed Web of Science ®Google Scholar
• Wang CC, Chiang YM, Sung SC, et al. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 2008;259:82–98.
   PubMed Web of Science ®Google Scholar
• Shih YW, Lee YC, Wu PF, et al. Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinaseplasminogen activator. Hepatol Res. 2009;39:998–1009.
   PubMed Web of Science ®Google Scholar
• Ding Y, Chen ZJ, Liu S, et al. Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. J Pharm Pharmacol. 2005;57:111–116.
   PubMed Web of Science ®Google Scholar
• Srinivas P, Gopinath G, Banerji A, et al. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog. 2004;40:201–211.
   PubMed Web of Science ®Google Scholar
• Vijayakumar R, Senthilvelan M, Ravindran R, et al. Plumbago zeylanica action on blood coagulation profile with and without blood volume reduction. Vascul Pharmacol. 2006;45:86–90.
   PubMed Web of Science ®Google Scholar
• Jeong SH, Choi JS, Ko YK, et al. The discovery of bioisoster compound for plumbagin using the knowledge-based rational method. J Mol Struct. 2015;1085:84–89.
   Web of Science ®Google Scholar
• Hsieh YJ, Lin LC, Tsai TH. Measurement and pharmacokinetic study of plumbagin in a conscious freely moving rat using liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;844:1–5.
   PubMed Web of Science ®Google Scholar
• Chen A, Zhou X, Tang S, et al. Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC–MS/MS and cocktail approach. Sci Rep. 2016;6:28482.
   PubMed Web of Science ®Google Scholar
• Bothiraja C, Pawar AP, Mali AJ, et al. Improved pharmaceutical properties of surface modified bioactive plumbagin crystals. Int J Surf Sci Eng. 2013;7:181–195.
   Web of Science ®Google Scholar
• Bardania H, Tarvirdipour S, Dorkoosh F. Liposome-targeted delivery for highly potent drugs. Artif Cells Nanomed Biotechnol. 2017;45:1478–1489.
   PubMed Web of Science ®Google Scholar
• Panahi Y, Farshbaf M, Mohammadhosseini M, et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif Cells Nanomed Biotechnol. 2017;45:788–799.
   PubMed Web of Science ®Google Scholar
• Tiwari SB, Pai RM, Udupa N. Temperature sensitive liposomes of plumbagin: characterization and in vivo evaluation in mice bearing melanoma B16F1. J Drug Target. 2002;10:585–591.
   PubMed Web of Science ®Google Scholar
• Sunil Kumar MR, Aithal BK, Udupa N, et al. Formulation of plumbagin loaded long circulating pegylated liposomes: in vivo evaluation in C57BL/6J mice bearing B16F1 melanoma. Drug Deliv. 2011;18:511–522.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.
   PubMed Web of Science ®Google Scholar
• Behnam B, Rezazadehkermani M, Ahmadzadeh A, et al. Microniosomes for concurrent doxorubicin and iron oxide nanoparticles loading; preparation, characterization and cytotoxicity studies. Artif Cells Nanomeds Biotechnol. 2017 [Apr 4]; [11 p.]. DOI:https://doi.org/10.1080/21691401.2017.1296850
   Google Scholar
• D’Souza Singh UV, Aithal KS, et al. Antifertility activity of niosomal HPβCD-Plumbagin complex. Indian J Pharm Sci. 1998;60:36–40.
   Google Scholar
• Oommen E, Dinesh Shenoy B, Udupa N, et al. Antitumour efficacy of cyclodextrin-complexed and harmac encapsulated plumbagin in mice bearing melanoma B16F1. Pharm Pharmacol Commun. 1999;5:281–285.
   Google Scholar
• Naresh RA, Udupa N, Devi PU. Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J Pharm Pharmacol. 1996;48:1128–1132.
   PubMed Web of Science ®Google Scholar
• Kini DP, Pandey S, Shenoy BD, et al. Antitumor and antifertility activities of plumbagin controlled release formulations. Indian J Exp Biol. 1997;35:374–379.
   PubMedGoogle Scholar
• Sah AK, Vyas A, Suresh PK, et al. Application of nanocarrier-based drug delivery system in treatment of oral cancer. Artif Cells Nanomeds Biotechnol. 2017 [Sep 7]; [8 p.]. DOI:https://doi.org/10.1080/21691401.2017.1373284
   Google Scholar
• Afsharzadeh M, Hashemi M, Mokhtarzadeh A, et al. Recent advance in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cells Nanomeds Biotechnol 2017 [Sep 28]; [16 p.]. DOI:https://doi.org/10.1080/21691401.2017.1376675
   Google Scholar
• Indhumathi D, Remya PN, Sangeetha S. Formulation trails on nanoparticular preparation for easy scale up through different techniques. J Chem Pharm Sci. 2013;6:170–174.
   Google Scholar
• Bothiraja C, Kapare HS, Pawar AP, et al. Development of plumbagin-loaded phospholipid-tween mixed micelles: formulation, optimization, effect on breast cancer cells and human blood/serum compatibility testing. Ther Deliv. 2013;4:1247–1259.
   PubMedGoogle Scholar
• Pawar A, Patel R, Arulmozhi S, et al. D-a-Tocopheryl polyethylene glycol 1000 succinate conjugated folic acid nanomicelles: towards enhanced bioavailability, stability, safety, prolonged drug release and synergized anticancer effect of plumbagin. RSC Adv. 2016;6:78106–78121.
   Web of Science ®Google Scholar
• Wang W, Lei Y, Sui H, et al. Fabrication and evaluation of nanoparticle-assembled BSA microparticles for enhanced liver delivery of glycyrrhetinic acid. Artif Cells Nanomeds Biotechnol. 2017;45:740–747.
   PubMed Web of Science ®Google Scholar
• Singh UV, Bisht KS, Rao S, et al. Plumbagin-loaded PLGA microspheres with and enhanced antitumour efficacy reduced in mice toxicity. Pharm Pharmacol Commun. 1996;2:407–409.
   Google Scholar
• Mandala RSK, Aithal K, Anandam A, et al. Preparation, in vitro characterization, pharmacokinetic, and harmacodynamics evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma. Drug Deliv. 2010;17:103–113.
   PubMed Web of Science ®Google Scholar
• Gorjikhah F, Jalalian FA, Salehi R, et al. Preparation and characterization of PLGA-β-CD polymeric nanoparticles containing methotrexate and evaluation of their effects on T47D cell line. Artif Cells Nanomeds Biotechnol. 2017;45:432–440.
   PubMed Web of Science ®Google Scholar
• Srinivas P, Patra CR, Bhattacharya S, et al. Cytotoxicity of naphthoquinones and their capacity to generate reactive oxygen species is quenched when conjugated with gold nanoparticles. Int J Nanomedicine. 2011;6:2113–2122.
   PubMed Web of Science ®Google Scholar
• Appadurai P, Rathinasamy K. Plumbagin-silver nanoparticle formulations enhance the cellular uptake of plumbagin and its antiproliferative activities. IET Nanobiotechnol. 2015;9:264–272.
   PubMed Web of Science ®Google Scholar
• Hafeez BB, Kashyap VK, Boya VN, et al. Novel nanoparticle formulation of Plumbagin for pancreatic cancer treatment. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl).
   Google Scholar
• Shahida Parveen SD, Affrose A, Suresh Kumar B, et al. Synthesis, characterization, and DNA binding studies of nanoplumbagin. J Nanomater. 2014;2014:9.
   Web of Science ®Google Scholar
• Duraipandy N, Lakra R, Kunnavakkam VS, et al. Caging of plumbagin on silver nanoparticles imparts selectivity and sensitivity to plumbagin for targeted cancer cell apoptosis. Metallomics. 2014;6:2025–2033.
   PubMed Web of Science ®Google Scholar
• Bothiraja C, Pawar AP, Mali AJ, et al. Improved pharmaceutical properties of surface modified bioactive plumbagin crystals. Int J Sur Sci Eng. 2013;7:181–195.
   Web of Science ®Google Scholar
• Rajalakshmi S, Pawar AP, Mali AJ, et al. Crystal engineering of bioactive plumbagin using anti-solvent precipitation, melt solidification and sonocrystallization techniques. Mater Res Express. 2014;1:1–19.
   Web of Science ®Google Scholar